暴露于HIV的早产儿拉米夫定给药方案:群体药代动力学建模与模拟研究
该研究整合8项新生儿和婴儿口服拉米夫定药代动力学研究数据,建立群体药代动力学模型并模拟早产儿给药策略,目标使AUC0-12维持在2.95至13.25 µg·h/mL参考范围内。模拟预测:胎龄≥24至<30周者从出生至体重达3 kg予2 mg/kg每日两次;胎龄≥30至<37周者出生后前4周予2 mg/kg每日两次,之后至体重达3 kg予4 mg/kg每日两次。作者认为模型预测支持上述按胎龄分层的每日两次给药方案,但需临床验证。
要点
- 共154名婴儿(59%为女性)贡献858个拉米夫定血浆浓度,出生胎龄中位数38周(范围27-41周)。
- 首次药代动力学采样时中位出生后日龄为6.3周(范围0.52-26.6周)。
- 模拟预测胎龄≥24至<30周予2 mg/kg每日两次至体重3 kg;胎龄≥30至<37周前4周2 mg/kg每日两次,之后4 mg/kg每日两次至体重3 kg。
核心结论
- 模型预测支持早产儿按胎龄分层给予拉米夫定每日两次的实用给药方案,但需临床验证。
研究设计与样本
- 整合8项新生儿和婴儿口服拉米夫定溶液药代动力学研究数据,采用非线性混合效应回归建立群体药代动力学模型。
- 在虚拟早产儿人群中模拟按出生胎龄分层的不同拉米夫定给药策略,目标维持AUC0-12在2.95至13.25 µg·h/mL参考范围内,直至≥4周龄且体重≥3 kg时切换为WHO体重分层剂量。
- 共154名婴儿(59%为女性)贡献858个拉米夫定血浆浓度;出生胎龄中位数38周(范围27-41周),首次采样时中位出生后日龄6.3周(范围0.52-26.6周)。
主要发现
- 拉米夫定浓度用一室模型描述,CL/F和V/F按体重进行异速缩放。
- CL/F的成熟过程用基于出生后日龄的Emax模型描述。
- CL/F还根据出生胎龄进行调整,以允许外推至极端早产儿。
关键数值与推荐
- 模拟预测胎龄≥24至<30周的婴儿从出生至体重达3 kg予拉米夫定2 mg/kg每日两次。
- 模拟预测胎龄≥30至<37周的婴儿出生后前4周予拉米夫定2 mg/kg每日两次,之后予4 mg/kg每日两次直至体重达3 kg。
- 目标拉米夫定AUC0-12参考范围为2.95至13.25 µg·h/mL。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 作者指出模型预测支持上述给药方案,但需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To develop a pragmatic twice daily lamivudine dosing strategy for preterm infants from 24 to 37 completed weeks of gestation. METHODS: Data were combined from eight pharmacokinetic studies in neonates and infants receiving lamivudine oral solution. A population pharmacokinetic model was developed using non-linear mixed effects regression. Different lamivudine dosing strategies, stratified by gestational age at birth (GA) bands, were simulated in a virtual population of preterm infants, aimed at maintaining lamivudine drug exposures (AUC0-12) within a reference target range of 2.95 to 13.25 µg·h/mL, prior to switching to WHO-weight band doses when ≥4 weeks of age and weighing ≥3 kg. RESULTS: A total of 154 infants (59% female) contributed 858 lamivudine plasma concentrations. Median (range) GA at birth was 38 (27-41) weeks. At the time of first pharmacokinetic sampling infants were older with median postnatal age (PNA) of 6.3 (0.52-26.6) weeks. Lamivudine concentrations were described by a one-compartment model, with CL/F and V/F allometrically scaled to weight. Maturation of CL/F was described using an Emax model based on PNA. CL/F was also adjusted on GA to allow extrapolation for extreme prematurity. Simulations predicted an optimal lamivudine dosing for infants GA ≥24 to <30 weeks of 2 mg/kg twice daily from birth until weighing 3 kg; and for GA ≥30 to <37 weeks, 2 mg/kg twice daily for the first 4 weeks of life, followed by 4 mg/kg twice daily until weighing 3 kg. CONCLUSIONS: Model-based predictions support twice daily pragmatic GA band dosing of lamivudine for preterm infants, but clinical validation is warranted.
引用
- Bekker A, Capparelli EV, Mirochnick M, et al. Lamivudine dosing for preterm infants exposed to HIV: a population pharmacokinetic modelling and simulation study. J Antimicrob Chemother. 2024. PMID: 39092932. doi:10.1093/jac/dkae259
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。